Wuhan Dazhong Dental Medical Co., Ltd. 武漢大眾口腔醫療股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2651） 截至2025年6月30日止六個月的中期業績公告 武漢大眾口腔醫療股份有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司 及其附屬公司（統稱「本集團」）截至2025年6月30日止六個月的未經審核綜合財務 業績。本公告包含本集團截至2025年6月30日止六個月的中期報告全文，其內容 是根據香港聯合交易所有限公司（「聯交所」）證券上市規則的相關披露要求編製。 董事會及本公司審核委員會已審閱本集團的未經審核綜合財務業績。本業績公告 於本公司網站( www.chinadzyl.com )及聯交所網站( www.hkexnews.hk )發佈。本公 司將按本公司H股股東選擇收取公司通訊的方式向其寄發截至2025年6月30日止 六個月的中期 ...

Core Viewpoint - The company, Dazhong Oral (02651.HK), announced a board meeting scheduled for August 29, 2025, to consider and approve its interim results for the six months ending June 30, 2025, and to discuss the potential distribution of an interim dividend, if any [1] Group 1 - The board meeting will take place on August 29, 2025 [1] - The meeting will focus on the approval of the company's interim results for the six months ending June 30, 2025 [1] - The company will also consider the distribution of an interim dividend during the meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會召開日期 武漢大眾口腔醫療股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公 司將於2025年8月29日（星期五）舉行董事會會議，藉以（其中包括）考慮及批准本 公司及其附屬公司截至2025年6月30日止六個月的中期業績及其發佈，並考慮派 發中期股息（如有）。 承董事會命 武漢大眾口腔醫療股份有限公司 董事長兼執行董事 姚雪先生 中國湖北省武漢 2025年8月18日 於本公告日期，本公司董事會包括(i)執行董事姚雪先生、沈洪敏女士、郭家平先 生及劉紅嬋女士；及(ii)獨立非執行董事疏義傑先生、黃素珍女士及王陶沙女士。 Wuhan Dazhong Dental Medical Co., Ltd. 武漢大眾口腔醫療股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2651） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 武漢大眾口腔醫療股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02651 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 17,026,140 | RMB | | 1 RMB | | 17,026,140 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 17,026,140 | RMB | | 1 RMB | | 17,026,140 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 ...

大众口腔(02651)发布公告，有关全球发售的稳定价格期已于2025年8月3日(星期日)(即递交香港公开发 售申请截止日期后第30日)结束。 独家整体协调人(为其本身及代表国际包销商)确认，概无国际发售的股份超额分配。因此，超额配股权 并未获行使，且超额配股权已失效。本公司获稳定价格操作人告知，稳定价格操作人(或任何代其行事 的人士)于稳定价格期并无采取稳定价格行动。 ...

Core Viewpoint - The global offering's stabilization period for Dazhong Oral (02651.HK) ended on August 3, 2025, with no over-allotment of shares confirmed by the exclusive overall coordinator [1] Summary by Relevant Sections - **Stabilization Period** The stabilization period for the global offering has concluded as of August 3, 2025, which is 30 days after the deadline for submitting the application for the Hong Kong public offering [1] - **Over-allotment and Stabilization Actions** The exclusive overall coordinator confirmed that there was no over-allotment of shares in the international offering. Consequently, the over-allotment option was not exercised and has lapsed. Additionally, the stabilization agent informed that no stabilization actions were taken during the stabilization period [1]

Core Viewpoint - The global offering's stabilization period for the company has ended on August 3, 2025, with no over-allotment of shares confirmed by the exclusive overall coordinator [1] Group 1 - The stabilization period concluded 30 days after the submission deadline for the Hong Kong public offering application [1] - The company did not exercise the over-allotment option, and it has now lapsed [1] - The stabilization agent informed that no stabilization actions were taken during the stabilization period [1]

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不會就本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 除本公告另有界定者外，本公告所用詞彙與武漢大眾口腔醫療股份有限公司（「本公司」）刊發日 期為2025年6月30日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告乃根據香港法例第571W章《證券及期貨（穩定價格）規則》第9(2)條作出。 本公告僅作說明用途，並不構成收購、購買或認購本公司任何證券的要約或誘使作出要約的邀 請。本公告並非招股章程。有意投資者於決定是否投資於發售股份前應閱覽招股章程，以獲得 有關本公司及下文所述全球發售的詳細資料。 本公告概不構成出售要約或要約購買的招攬，而在任何作出有關要約、招攬或出售即屬違法的 司法管轄區內，概不得出售任何發售股份。本公告不會直接或間接於或向美國（包括美國的領 土及屬地、美國任何州以及哥倫比亞特區）發佈、刊發或派發。本公告並不構成亦不屬於在美 國境內或於任何其他司法管轄區購買或認購證券的任何要約或招攬的一部分。發售股份不曾亦 不會 ...

Core Viewpoint - Wuhan Dazhong Dental Medical Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for Hubei enterprises in the capital market [1] Group 1: Company Overview - Dazhong Dental was established in 2007 and operates 92 institutions, including 4 hospitals and 80 outpatient departments, across 8 cities in Hubei and Hunan provinces [2] - As of 2023, Dazhong Dental holds the largest market share of approximately 2.6% among private dental service providers in Central China [2] - The company previously listed on the New Third Board in 2015 but voluntarily delisted in 2018 [2] Group 2: Financial Performance - Dazhong Dental's revenue for 2022, 2023, and 2024 was 409 million yuan, 442 million yuan, and 407 million yuan respectively, with adjusted net profits of 59.38 million yuan, 70.42 million yuan, and 68.35 million yuan [2] - The company attributed the decline in 2024 performance to consumer downgrade and intensified competition in the dental service industry [2] - Revenue breakdown for 2024 includes 217 million yuan from comprehensive dental services (53.4%), 116 million yuan from dental implant services (28.4%), and 74.12 million yuan from orthodontic services (18.2%) [2] Group 3: IPO Details - Dazhong Dental's IPO price was set at 20 HKD, with a total issuance of 10.86 million shares, raising a total of 217 million HKD [3] - After deducting listing expenses of 39.07 million HKD, the net proceeds amount to 178 million HKD [3] - The planned allocation of the raised funds includes 35% for establishing new dental institutions, 25% for acquisitions, 10% for upgrading existing facilities, 10% for IT infrastructure, 10% for developing medical teams, and 10% for working capital [3] Group 4: Market Context - The IPO activity in Hong Kong has been increasing, with several Hubei enterprises successfully listing, including Yuanguang Technology and Xiangjiang Electric [4] - Yuanguang Technology, which operates a major public transport app, and Xiangjiang Electric, a manufacturer with significant revenue growth, highlight the trend of Hubei companies entering the Hong Kong market [4]

Summary of Key Points Core Viewpoint - The Hong Kong IPO market is experiencing significant activity, with multiple companies filing for listings and a notable increase in market liquidity and new listings compared to the previous year [14]. Group 1: Company Filings - Three companies submitted applications for IPOs: 1. **Shenzhen Xingyuan Material Technology Co., Ltd.** specializes in lithium-ion battery separators and holds the largest market share in dry-process separators globally, with projected revenues of 2.867 billion, 2.982 billion, 3.506 billion, and 881 million RMB from 2022 to 2025 [2]. 2. **LXJ International Holdings Limited (Laoxiangji)** operates a fast-food chain with 1,564 stores across 55 cities, achieving revenues of approximately 4.528 billion, 5.651 billion, 6.288 billion, and 2.120 billion RMB from 2022 to 2025 [3][4]. 3. **Lianqi Technology Co., Ltd.** is a leading fabless integrated circuit design company, with revenues of approximately 3.672 billion, 2.286 billion, 3.639 billion, and 1.222 billion RMB from 2022 to 2025 [5]. Group 2: IPO Activity - No companies passed the hearing last week, but one company, **Shougang Longze**, is restarting its IPO process, planning to offer 20.1598 million H-shares at a price range of 14.5 to 18.88 HKD per share [6][7]. Group 3: New Listings - Six new stocks were listed last week, including: 1. **Fuwai Group**: Closed at 38.40 HKD with a gain of 1.05% [8]. 2. **Lens Technology**: Closed at 19.84 HKD with a gain of 9.13% [9]. 3. **Dazhong Oral**: Closed at 20.70 HKD with a gain of 3.50% [10]. 4. **Xunzhong Co.**: Closed at 13.58 HKD with a gain of 0.22% [11]. 5. **Jizhi Jia-W**: Closed at 17.70 HKD with a gain of 5.36% [12]. 6. **Fortior**: Closed at 139.80 HKD with a gain of 16.02% [13]. Group 4: Market Trends - The Hong Kong stock market has seen a significant improvement in liquidity, with an average daily trading volume of 240.2 billion HKD in the first half of 2025, a 118% increase from the previous year [14]. - The number of new listings increased to 44 in the first half of 2025, up 47% from the previous year, with total fundraising amounting to 107.1 billion HKD, a 699% increase [14].